Top 5 BiPAP Machines in India (2026)

The BiPAP (bilevel positive airway pressure) machine is the correct class for patients whose clinical picture is not served by a CPAP — central sleep apnoea, CPAP-failure OSA, obesity hypoventilation syndrome (OHS), COPD-OSA overlap with hypercapnia, neuromuscular disease with preserved spontaneous breathing, and severe hypoventilation that needs volume-assured pressure support (iVAPS, AVAPS, TVAPS). It is not a default upgrade from CPAP. This listicle ranks the five BiPAP machines HHZ considers the strongest buys for Indian households in 2026 by editorial score. The default pick for any patient with documented nocturnal hypoventilation is the ResMed Lumis 150 VPAP ST — the only iVAPS-capable unit in the list with native cloud connectivity.

How we ranked

HHZ applies the same rubric to every BiPAP: pressure range (2–25 cmH₂O minimum for adult NIV), therapy mode set (CPAP/S/ST/T/PAC/iVAPS or AVAPS or TVAPS), backup-rate intelligence, central-apnoea detection, published sound level, weight, integrated humidification, cloud connectivity for clinician-side remote titration, altitude compensation, Indian authorised-dealer depth, warranty term, and price-to-performance against in-class alternatives. We do not run bench tests — all performance claims are per published spec, manufacturer brochure, or field-observed in the dealer network. The full methodology is at our methodology page.

The top 5

1. ResMed Lumis 150 VPAP ST — 8.5

Price snapshot — indicative retail ₹63,490 (listed MRP ₹138,000), 1.26 kg, 2–25 cmH₂O pressure range, 25 dB published sound, six therapy modes (iVAPS, CPAP, S, ST, T, PAC), native cellular connectivity, 2-year manufacturer warranty (sometimes 3-year dealer extension), FDA/FAA/CE approved.

Pros

• iVAPS (Intelligent Volume-Assured Pressure Support) mode targets alveolar ventilation rather than fixed pressure — the published standard-of-care for severe OHS, advanced neuromuscular disease, and chronic hypercapnic COPD.
• Full six-mode therapy set (iVAPS, CPAP, S, ST, T, PAC) covers essentially every home-NIV clinical indication on a single chassis.
• Cloud connectivity/Wi-Fi published as Yes — native AirView integration for remote titration, which hypoventilation management genuinely needs across the first 2–4 weeks of therapy.
• iBR (Intelligent Backup Rate) delivers backup breaths only during real apnoeas or effort failures, not benign sighs or coughs — meaningful for NMD patients with variable effort.
• Ti Control, Trigger and Cycle Sensitivity, Rise Time all configurable — complete clinical tuning envelope. VSync leak compensation keeps iVAPS ventilation estimates clean through mask leak.
• Full HumidAir plus ClimateLineAir heated-tube climate control; Auto Ramp and Ramp Down; Pressure Support published as a directly-readable clinical parameter.

Cons

• ₹63,490 retail sits at the top of the home-BiPAP bracket and is only justified when iVAPS is clinically indicated — uncomplicated OSA patients should not be on this device.
• iVAPS commissioning requires clinician setup with target alveolar ventilation and baseline spirometry — not a plug-and-play device.
• Weight at 1.26 kg and footprint matches the Lumis 100 — no portability advantage over the cheaper sibling.
• ₹15,590 premium over the Lumis 100 is only defensible when iVAPS or native cloud connectivity is the load-bearing requirement.

Best for — severe OHS (BMI >45, daytime PaCO₂ >55 mmHg), advanced NMD (ALS with FVC <50% predicted, DMD transitioning to nocturnal NIV), chronic hypercapnic COPD needing high-intensity NIV, any hospital-to-home transition after acute hypercapnic respiratory failure where ventilation targets from ICU need to be maintained.

Full review at /bipap/resmed-lumis-vpap-st-bipap-tripack/.

2. ResMed Lumis 100 VPAP ST — 8.4

Price snapshot — indicative retail ₹47,900 (listed MRP ₹107,520), 1.2 kg, 2–25 cmH₂O pressure range, 25 dB published sound, five therapy modes (CPAP, S, ST, T, PAC), 2-year manufacturer warranty (sometimes 3-year dealer extension), FDA/FAA/CE approved.

Pros

• Full five-mode clinical stack (CPAP, S, ST, T, PAC) with Intelligent Backup Rate covers central apnoea, NMD with preserved spontaneous effort, COPD-OSA overlap with mild hypercapnia, and moderate OHS.
• iBR logic distinguishes real apnoeas from benign respiratory pauses, delivering backup breaths only when clinically warranted — meaningfully better patient-ventilator synchrony than plain backup-rate BiPAPs.
• PAC mode (Pressure Assist Control) — fixed-Ti time-cycled mode for patients with unreliable inspiratory effort. Not available on the discontinued AirCurve 10 ST.
• ₹47,900 retail is ₹19,288 below the discontinued AirCurve 10 ST and ₹15,590 below the iVAPS-capable Lumis 150 — the best-value clinical ST BiPAP in the Indian market.
• 2–25 cmH₂O pressure range plus full Ti Control, Trigger/Cycle Sensitivity, and Rise Time tuning — complete clinical control envelope.
• 25 dB published sound and full HumidAir/ClimateLineAir climate control match the Lumis 150 comfort stack.

Cons

• Cloud connectivity/Wi-Fi published as No on the base SKU — data upload to AirView requires manual SD-card retrieval unless the cellular-module-equipped SKU is specified at purchase.
• No iVAPS — severe OHS and NMD patients with documented nocturnal hypoventilation need to step up to the Lumis 150.
• Pressure Support is blank on the spec sheet; device delivers fixed IPAP/EPAP bilevel with pressure support as the numerical difference, rather than a PS-targeted algorithm.
• Not the right device for ASV-indicated patients (severe complex sleep apnoea, treatment-emergent CSA, heart-failure periodic breathing).

Best for — central sleep apnoea (CAI >5/hour) without severe cardiac component, NMD with preserved spontaneous effort, COPD-OSA overlap with PaCO₂ 45–55 mmHg, moderate OHS (BMI 35–45, PaCO₂ 45–50) before iVAPS is clinically required.

Full review at /bipap/resmed-lumis-100-vpap-st-bipap/.

3. ResMed AirCurve 10 V Auto — 8.2

Price snapshot — indicative retail ₹66,800 (listed MRP ₹81,600), 1.24 kg, 3–25 cmH₂O pressure range, 25 dB published sound, three therapy modes (CPAP, S, VAuto), native cellular connectivity, 2-year manufacturer warranty (sometimes 3-year dealer extension), FDA/FAA/CE approved.

Pros

• VAuto mode delivers auto-adjusting IPAP with configurable minimum pressure support — the clinically mature auto-BiPAP algorithm for CPAP-failure OSA and complex apnoea without central component.
• Pressure Support is explicitly published as Yes on the spec sheet and exposed as a directly-set parameter — distinguishes VAuto from plain S-mode bilevel.
• Built-in cellular modem plus AirView compatibility — nightly data upload enables clinic-led remote titration, which serial IPAP/EPAP/PS/rise-time adjustments in the first 3–6 months of therapy genuinely need.
• 3–25 cmH₂O pressure range covers the full adult-OSA, CPAP-failure, and mild-to-moderate OHS window; full HumidAir plus ClimateLineAir climate control.
• 25 dB published sound, 1.24 kg, matches the AirSense 10 comfort envelope.
• Leakage Compensation and Mask Fit verification — critical for BiPAP where mask leak corrupts cycle-sensitivity signals.

Cons

• ₹66,800 retail is roughly ₹20,000 above the AirSense 11 APAP — many OSA patients prescribed BiPAP do not actually need bilevel therapy.
• Spec-sheet blanks on RERA reporting and Backup Rate — this is not the right machine for patients with central apnoea, neuromuscular indications, or hypoventilation.
• No iVAPS, no true volume-assurance — OHS and NMD patients need a Lumis 150, not this device.
• Not a device for treatment-emergent central sleep apnoea — ASV-class therapy is the correct escalation, not VAuto.

Best for — documented CPAP-failure OSA (AHI >5 on AirSense 10/11 despite proper titration, or documented CPAP intolerance), complex sleep apnoea with CAI 2–5/hour (below ASV threshold), mild-to-moderate OHS without iVAPS-level hypoventilation, COPD-OSA overlap with obstructive-dominant burden and mild hypercapnia.

Full review at /bipap/resmed-aircurve-v-auto/.

4. Home Medix HM-BV-30 — 8.0

Price snapshot — indicative retail ₹29,000 (listed MRP ₹45,000), 1.45 kg with integrated humidifier, 4–30 cmH₂O pressure range, <30 dB published sound, seven therapy modes (CPAP, APAP, S, Auto S, S/T, T, TVAPS), ISO 9001 + ISO 13485 + CDSCO approved.

Pros

• TVAPS (target-volume assured pressure support) at a sub-premium tier — functionally equivalent to ResMed iVAPS and Philips AVAPS, and not listed by the closest Indian competitor BMC G3 B30VT.
• Full seven-mode clinical stack (CPAP, APAP, S, Auto S, S/T, T, TVAPS) covers straightforward OSA through volume-assured home NIV on a single chassis.
• 4–30 cmH₂O pressure envelope — 5 cmH₂O higher ceiling than the Lumis platform — covers high-IPAP severe obesity-hypoventilation and elevated-pressure severe OSA.
• 1.45 kg with integrated heated humidifier is lighter than the BMC G3 B30VT (1.7 kg) and competitive with the Philips DreamStation class. Bedside-credible chassis.
• Backup rate in T and S/T modes, central-apnea detection (OSA/CSA) in the published spec — feature coverage that closest competitors at this price omit.
• Patented SAF algorithm with leak-compensated synchronization and multi-level event detection (flow limitation, multi-frequency snoring, multi-severity hypopnea).
• ₹29,000 retail is substantially below the Lumis 150’s ₹63,490 — TVAPS reachable for households pushed out of the ResMed ST-A tier by budget.

Cons

• No CE and no FDA listed on the published spec — weaker paperwork for hospital-channel procurement and international travel clearance.
• No Wi-Fi, no cloud, no SD card, no Bluetooth — clinics standardised on AirView or Care Orchestrator cannot integrate compliance data.
• No heated-tube compatibility, no climate control, no adaptive humidification — real four-season comfort gap versus ResMed or Philips premium tier.
• Central-apnea DETECTION only, not ASV-class treatment — CompSA and cardiac-origin central events still escalate to a ResMed AirCurve ASV or Philips DreamStation ASV.
• Service-network coverage strongest in South/West India; North-East and remote reach is thin, which is non-trivial for a home-NIV device where nightly downtime is not acceptable.

Best for — OHS, progressive NMD, and complex-NIV home prescriptions where the physician requires volume-assured ventilation and the budget cannot reach the ResMed AirCurve ST-A tier, BiPAP-complexity patients with mixed apnoea plus central events managed in Home-Medix-served cities.

Full review at /bipap/home-medix-bv-30/.

5. Philips DreamStation BiPAP AVAPS — 8.0

Price snapshot — indicative retail ₹77,952 (listed MRP ₹142,080), 1.98 kg with humidifier, 4–30 cmH₂O pressure range, 26.1 dB published sound, full CPAP/S/S-T/PC/T/AVAPS mode range, Care Orchestrator cloud, Bluetooth, FAA approved, CE certified (FDA not stated for this Indian SKU).

Pros

• AVAPS (Average Volume Assured Pressure Support) plus AVAPS-AE auto-titration — handles OHS, late-stage COPD with chronic hypercapnia, and neuromuscular disease that pure S/ST BiPAPs cannot deliver safely.
• 4–30 cmH₂O pressure envelope with full CPAP/S/S-T/PC/T/AVAPS mode range — one of only two Indian-available BiPAPs here covering both the 30 cmH₂O ceiling and the mode depth.
• Digital Auto-Trak trigger detection with Auto Back-up Rate — sophisticated ventilator logic that Indian pulmonologists prescribing home AVAPS specifically ask for.
• 1.98 kg with humidifier, 26.1 dB sound, FAA approval, and Care Orchestrator cloud integration — meaningful travel capability for a clinical BiPAP class that traditionally stays bedside.
• Auto Ramp, Auto On/Off, EPR, preheat, adaptive humidification, climate control, heated-tube compatibility, mask fit — full comfort stack for a sick-patient population where adherence is load-bearing.
• Philips India’s authorised service network is the deepest among imported BiPAP brands in India.

Cons

• 2021 Philips Respironics PE-PUR foam recall — largely remediated by 2026, but AVAPS patients are the sickest in the DreamStation population and serial-number verification of remediation status is non-negotiable at purchase.
• ₹77,952 retail is premium — ₹14,462 above the Lumis 150 with similar capability, where the Lumis carries no recall-remediation history.
• No integrated battery — a gap for AVAPS patients needing mobility beyond the bedside; external inverter-UPS add-ons are a mandatory planning step.
• SpO₂ monitoring compatibility is not listed in the published additional-details table for this Indian SKU — verify with the supplier if pulse-oximetry co-recording is a clinical requirement.
• 2-year Indian warranty trails ResMed’s 3-year Lumis dealer-extension warranty by a year.

Best for — respiratory-physician prescriptions explicitly requiring volume-assured ventilation where the clinic runs Care Orchestrator (not AirView), overlap syndromes (OSA plus OHS) needing AVAPS-AE auto-titration, patients whose trust in Philips post-recall is intact given documented remediation.

Full review at /bipap/philips-dreamstation-bipap-avaps/.

How to pick between these five

The indication decides the device. BiPAP is not one class — it is four overlapping therapies (spontaneous bilevel, ST backup-rate, auto-BiPAP, volume-assured) served by different machine tiers. Map the indication first, then pick the machine:

• CPAP-failure OSA or complex sleep apnoea without central burden → AirCurve 10 V Auto. VAuto’s auto-IPAP with configurable minimum PS is the correct algorithm. Lumis 100 and Lumis 150 are over-specified; HM-BV-30 and DreamStation AVAPS are over-specified.
• Central sleep apnoea, NMD with preserved effort, moderate OHS, COPD-OSA overlap with mild hypercapnia → Lumis 100 VPAP ST. iBR backup-rate intelligence is the correct feature. VAuto lacks backup rate.
• Severe OHS (BMI >45, PaCO₂ >55), advanced NMD, chronic hypercapnic COPD, documented nocturnal hypoventilation → Lumis 150 VPAP ST (iVAPS) or DreamStation BiPAP AVAPS. Volume-assured ventilation is non-substitutable at this clinical tier. Between the two, pick based on clinic platform (AirView = Lumis 150; Care Orchestrator = DreamStation AVAPS) and recall-comfort preference.
• Same severe-indication patient at a sub-premium budget → HM-BV-30. TVAPS at ₹29,000 is the only Indian-market answer for volume-assured therapy when the Lumis 150 or DreamStation AVAPS budgets are out of reach. Real clinical coverage trade for narrower paperwork and no cloud.

Cloud integration matters more on BiPAP than on CPAP. A CPAP stabilises within weeks of titration; a BiPAP often needs serial IPAP, EPAP, PS, rise-time, and Ti adjustments over the first 3–6 months. Three units in the list ship native cellular — Lumis 150, AirCurve 10 V Auto, DreamStation BiPAP AVAPS. The Lumis 100 base SKU has cellular as optional — confirm “With Cellular” at purchase if the clinic runs AirView. The HM-BV-30 has no cloud pathway. For clinics running remote titration, the cloud-enabled four are the shortlist.

Sound and chassis. All five units sit at 25–30 dB published — all below bedside-disruption threshold in a typical Indian bedroom. The DreamStation BiPAP AVAPS is the heaviest in the list at 1.98 kg (with humidifier); the Lumis 100 the lightest at 1.2 kg. None of these are travel-portable BiPAPs — the category of travel-BiPAP effectively does not exist in India at a price point we can recommend.

Warranty and recall history. The Lumis platform carries 2-year manufacturer, often 3-year dealer extension — the longest in the list. The AirCurve 10 V Auto matches Lumis on warranty term. The DreamStation AVAPS is 2 years manufacturer, with the 2021 foam-recall serial-number verification as the one non-negotiable purchase-time step. The HM-BV-30 ships a 3-year or 10,000-hour warranty consistent with the Home Medix platform; no recall history to verify.

Price. The HM-BV-30 at ₹29,000 is the cheapest; the DreamStation AVAPS at ₹77,952 the most expensive. The Lumis 100 at ₹47,900 is the value sweet spot for the ST indications where iVAPS is not clinically required. The AirCurve 10 V Auto at ₹66,800 is the correct spend only on a VAuto-indicated patient; stepping down to the AirSense 11 at ₹63,390 for uncomplicated OSA saves the BiPAP premium.

Who should look elsewhere

Patients with uncomplicated obstructive sleep apnoea (AHI 15–50, no central component, no hypoventilation, no CPAP trial history) should not be on any BiPAP in this list. The correct first-line device is a CPAP or APAP — see our CPAP top 5. Prescribing BiPAP first-line to CPAP-naive uncomplicated OSA is clinically wasteful.

Patients with severe complex sleep apnoea, treatment-emergent central sleep apnoea, or heart-failure periodic breathing need ASV (adaptive servo-ventilation) platforms — ResMed AirCurve 10 ASV or Philips DreamStation ASV — not any of the units in this list. ST-mode backup rate is not a substitute for ASV’s pressure-support modulation.

Patients on full or near-full ventilator dependence (late-stage ALS with daytime ventilation, chronic tracheostomy ventilation, post-polio respiratory failure) need dedicated home ventilators (Philips Trilogy, ResMed Astral, Breas Vivo) — life-support-certified devices with dual-circuit operation, multi-tier alarms, and internal battery backup. None of the five units in this list carries ventilator certification or internal battery; a BiPAP with volume-assurance is not a ventilator.

Patients in Indian hill stations above 2,591 m (Leh, Kaza, Spiti villages) should note that published altitude-compensation specifications on these units generally cap around 2,591 m. For long-term residence at higher altitudes, confirm delivered-pressure stability with the brand’s Indian service centre before committing.

Buyers in tier-3 cities or rural districts where no authorised ResMed, Philips, or Home Medix service partner sits within a 72-hour dispatch radius should either commit to a metro-relocation plan for service or negotiate a written loaner-unit clause for BiPAP-dependent patients who cannot lose a night of therapy.

Patients or households whose trust in Philips Respironics post-2021 recall is not intact — even for documented-remediated DreamStation 1 units or DreamStation 2 platform units — should default to the Lumis 150 for AVAPS-equivalent therapy.

Verdict

For the default home-NIV patient with documented nocturnal hypoventilation — severe OHS, advanced NMD, chronic hypercapnic COPD — the ResMed Lumis 150 VPAP ST at ₹63,490 is the right pick. iVAPS mode, full six-mode clinical stack, native AirView cellular, iBR backup-rate intelligence, VSync leak management, 3-year dealer-extension warranty. The price is defensible when iVAPS is clinically required.

For ST-mode backup-rate indications without hypoventilation — central sleep apnoea, NMD with preserved effort, moderate OHS, COPD-OSA overlap with mild hypercapnia — the ResMed Lumis 100 VPAP ST at ₹47,900 is the best-value clinical ST BiPAP in the Indian market. Same five-mode stack minus iVAPS, iBR, PAC mode, and a decade-mature comfort envelope.

For documented CPAP-failure OSA or complex sleep apnoea without central burden, the ResMed AirCurve 10 V Auto at ₹66,800 is the correct auto-BiPAP pick — but only on a documented CPAP-failure or complex-apnoea indication. Do not default-upgrade an uncomplicated OSA patient from AirSense to AirCurve.

For volume-assured home NIV patients whose budget cannot reach the Lumis 150 or DreamStation AVAPS tier, the Home Medix HM-BV-30 at ₹29,000 is the defensible answer. TVAPS at sub-premium pricing is genuinely rare in the Indian market, and the seven-mode stack plus central-apnea detection clears the functional bar. The trade is no cloud, no heated tube, and service coverage concentrated in South and West India.

For AVAPS-indicated patients in clinics on Philips Care Orchestrator platform (rather than ResMed AirView), the Philips DreamStation BiPAP AVAPS at ₹77,952 is the defensible alternative to the Lumis 150 — with mandatory serial-number verification of foam-remediation status at purchase.

Consult your prescribing respiratory physician before finalising any BiPAP purchase against your specific PSG and clinical picture — BiPAP indication is where many Indian patients are mis-specced into a therapy tier that does not match the disease.